T1	PROC 49 171	Estudio a 12 semanas, prospectivo, multicéntrico, a doble ciego, aleatorizado, controlado con placebo, de grupos paralelos
T2	PROC 178 214	evaluar la seguridad y tolerabilidad
T3	DISO 445 461	condición médica
#1	AnnotatorNotes T3	C4745084; Medical Condition; Finding
T4	DISO 244 265	hipertensión pulmonar
#2	AnnotatorNotes T4	C0020542; Pulmonary Hypertension; Pathologic Function
T5	DISO 316 348	disfunción ventricular izquierda
#3	AnnotatorNotes T5	C0242698; Ventricular Dysfunction, Left; Pathologic Function
T6	DISO 375 404	disfunción cardíaca izquierda
T7	ANAT 386 394	cardíaca
#4	AnnotatorNotes T7	C0018787; Heart; Body Part, Organ, or Organ Component | C1281570; Entire heart; Body Part, Organ, or Organ Component
T8	DISO 418 439	hipertensión pulmonar
#5	AnnotatorNotes T8	C0020542; Pulmonary Hypertension; Pathologic Function
T9	ANAT 496 512	vasos sanguíneos
#6	AnnotatorNotes T9	C0005847; Blood Vessel; Body Part, Organ, or Organ Component | C1283786; Entire blood vessel; Body Part, Organ, or Organ Component
T10	ANAT 527 535	pulmones
#7	AnnotatorNotes T10	C0024109; Lung; Body Part, Organ, or Organ Component | C1278908; Entire lung; Body Part, Organ, or Organ Component
T11	DISO 588 609	Hipertensión pulmonar
#8	AnnotatorNotes T11	C0020542; Pulmonary Hypertension; Pathologic Function
T12	DISO 660 692	disfunción ventricular izquierda
#9	AnnotatorNotes T12	C0242698; Ventricular Dysfunction, Left; Pathologic Function
T13	DISO 778 799	hipertensión pulmonar
#10	AnnotatorNotes T13	C0020542; Pulmonary Hypertension; Pathologic Function
T14	DISO 850 882	disfunción ventricular izquierda
#11	AnnotatorNotes T14	C0242698; Ventricular Dysfunction, Left; Pathologic Function
T15	PROC 915 936	Tratamiento diurético
T16	DISO 988 1009	hipertensión pulmonar
#12	AnnotatorNotes T16	C0020542; Pulmonary Hypertension; Pathologic Function
T17	DISO 1150 1153	PAH
T18	DISO 1127 1148	hipertensión pulmonar
#13	AnnotatorNotes T18	C0020542; Pulmonary Hypertension; Pathologic Function
T19	CHEM 1217 1229	prostanoides
#14	AnnotatorNotes T19	C0033554; Prostaglandins; Hormone · Organic Chemical · Pharmacologic Substance
T20	CHEM 1231 1267	inhibidores de la fosfodiesterasea-5
#15	AnnotatorNotes T20	C1318700; Phosphodiesterase 5 inhibitor; Pharmacologic Substance
T21	CHEM 1269 1274	PDE-5
T22	CHEM 1277 1313	estimulantes de la guanilato ciclasa
#16	AnnotatorNotes T22	C3819023; Soluble Guanylate Cyclase Stimulator; Pharmacologic Substance (?)
T23	CHEM 218 228	macitentan
#17	AnnotatorNotes T23	C2606556; Macitentan; Organic Chemical · Pharmacologic Substance
T24	ANAT 257 265	pulmonar
#18	AnnotatorNotes T24	C0034052; Pulmonary artery structure; Body Part, Organ, or Organ Component | C1269026; Entire pulmonary artery; Body Part, Organ, or Organ Component
T25	ANAT 327 338	ventricular
#19	AnnotatorNotes T25	C0018827; Heart Ventricle; Body Part, Organ, or Organ Component | C1280934; Entire cardiac ventricle; Body Part, Organ, or Organ Component
T26	ANAT 431 439	pulmonar
#20	AnnotatorNotes T26	C0034052; Pulmonary artery structure; Body Part, Organ, or Organ Component | C1269026; Entire pulmonary artery; Body Part, Organ, or Organ Component
T27	ANAT 601 609	pulmonar
#21	AnnotatorNotes T27	C0034052; Pulmonary artery structure; Body Part, Organ, or Organ Component | C1269026; Entire pulmonary artery; Body Part, Organ, or Organ Component
T28	ANAT 671 682	ventricular
#22	AnnotatorNotes T28	C0018827; Heart Ventricle; Body Part, Organ, or Organ Component | C1280934; Entire cardiac ventricle; Body Part, Organ, or Organ Component
T29	ANAT 791 799	pulmonar
#23	AnnotatorNotes T29	C0034052; Pulmonary artery structure; Body Part, Organ, or Organ Component | C1269026; Entire pulmonary artery; Body Part, Organ, or Organ Component
T30	ANAT 861 872	ventricular
#24	AnnotatorNotes T30	C0018827; Heart Ventricle; Body Part, Organ, or Organ Component | C1280934; Entire cardiac ventricle; Body Part, Organ, or Organ Component
T31	ANAT 1001 1009	pulmonar
#25	AnnotatorNotes T31	C0034052; Pulmonary artery structure; Body Part, Organ, or Organ Component | C1269026; Entire pulmonary artery; Body Part, Organ, or Organ Component
T32	PROC 1078 1107	Administración de tratamiento
T33	ANAT 1140 1148	pulmonar
#26	AnnotatorNotes T33	C0034052; Pulmonary artery structure; Body Part, Organ, or Organ Component | C1269026; Entire pulmonary artery; Body Part, Organ, or Organ Component
T34	CHEM 1166 1208	antagonistas del receptor de la endotelina
T35	Date 13 17	2013
T36	Duration 59 69	12 semanas
T37	LIVB 232 239	sujetos
#27	AnnotatorNotes T37	C0681850; Study Subject; Group
T38	Spec_cue 405 410	puede
T39	PHYS 481 512	presión de los vasos sanguíneos
#28	AnnotatorNotes T39	C0005823; Blood Pressure; Organism Function
T40	LIVB 732 739	mujeres
#29	AnnotatorNotes T40	C0043210; Woman; Population Group
T41	Age 753 762	>=18 años
T42	LIVB 766 773	Sujetos
#30	AnnotatorNotes T42	C0681850; Study Subject; Group
T44	LIVB 722 729	Varones
#31	AnnotatorNotes T44	C0025266; Male population group; Population Group
A1	Assertion T8 Speculated
#32	AnnotatorNotes T2	C3274448; Tolerability Study; Research Activity + C1705187; Safety Study; Research Activity
#33	AnnotatorNotes T6	C0242698; Ventricular Dysfunction, Left; Pathologic Function
#34	AnnotatorNotes T15	C0948575; Diuretic therapy; Therapeutic or Preventive Procedure 
#35	AnnotatorNotes T17	C0020542; Pulmonary Hypertension; Pathologic Function
#36	AnnotatorNotes T34	C1134681; Endothelin receptor antagonist; Pharmacologic Substance 
#37	AnnotatorNotes T21	C1318700; Phosphodiesterase 5 inhibitor; Pharmacologic Substance
T43	Neg_cue 1010 1022	distintos de
T45	Quantifier_or_Qualifier 1027 1053	grupos 2.1 y 2.2 de la WHO
A2	Assertion T45 Negated
R1	Has_Duration_or_Interval Arg1:T1 Arg2:T36	
R2	Experiences Arg1:T37 Arg2:T23	
R3	Experiences Arg1:T37 Arg2:T4	
R4	Location_of Arg1:T24 Arg2:T4	
T47	Quantifier_or_Qualifier 266 298	combinada postcapilar-precapilar
R5	Has_Quantifier_or_Qualifier Arg1:T4 Arg2:T47	
R6	Causes Arg1:T5 Arg2:T4	
R7	Location_of Arg1:T25 Arg2:T5	
R8	Experiences Arg1:T37 Arg2:T5	
R9	Location_of Arg1:T7 Arg2:T6	
R10	Speculation Arg1:T38 Arg2:T8	
R11	Before Arg1:T6 Arg2:T8	
T48	Quantifier_or_Qualifier 462 467	grave
#38	AnnotatorNotes T48	C1547227; Severe - Severity of Illness Code; Intellectual Product
R12	Has_Quantifier_or_Qualifier Arg1:T3 Arg2:T48	
R13	Location_of Arg1:T9 Arg2:T39	
R14	Location_of Arg1:T10 Arg2:T8	
R15	Location_of Arg1:T26 Arg2:T8	
R17	Location_of Arg1:T10 Arg2:T3	
T49	Result_or_Value 539 560	más alta de lo normal
R18	Has_Result_or_Value Arg1:T39 Arg2:T49	
R19	Location_of Arg1:T27 Arg2:T11	
R20	Location_of Arg1:T29 Arg2:T13	
R21	Location_of Arg1:T28 Arg2:T12	
R22	Causes Arg1:T12 Arg2:T11	
R23	Causes Arg1:T14 Arg2:T13	
R24	Location_of Arg1:T30 Arg2:T14	
T50	Quantifier_or_Qualifier 610 642	combinada postcapilar-precapilar
R25	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T50	
T51	Quantifier_or_Qualifier 800 832	combinada postcapilar-precapilar
R26	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T51	
R27	Has_Age Arg1:T40 Arg2:T41	
R28	Has_Age Arg1:T44 Arg2:T41	
R29	Experiences Arg1:T42 Arg2:T13	
R30	Experiences Arg1:T42 Arg2:T14	
T52	Quantifier_or_Qualifier 937 943	óptimo
R31	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T52	
R32	Location_of Arg1:T31 Arg2:T16	
R33	Negation Arg1:T43 Arg2:T45	
T46	Quantifier_or_Qualifier 884 909	grupo 2.1 y 2.2 de la WHO
R34	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T46	
R35	Has_Quantifier_or_Qualifier Arg1:T16 Arg2:T45	
R36	Location_of Arg1:T33 Arg2:T18	
R37	Location_of Arg1:T33 Arg2:T17	
R38	Used_for Arg1:T34 Arg2:T32	
R39	Used_for Arg1:T19 Arg2:T32	
#39	AnnotatorNotes T32	C3469597; Administration of medication; Therapeutic or Preventive Procedure
R40	Used_for Arg1:T20 Arg2:T32	
R41	Used_for Arg1:T21 Arg2:T32	
R42	Used_for Arg1:T22 Arg2:T32	
#40	AnnotatorNotes T52	C2698651; Optimum; Qualitative Concept
A3	Experiencer T37 Patient
A4	Experiencer T40 Patient
A5	Experiencer T44 Patient
A6	Experiencer T42 Patient
